Table 1 Prevalence of pre-clinical stroke guidelines in stroke studies using NOX knockout mice
From: The 1027th target candidate in stroke: Will NADPH oxidase hold up?
NOX isoform | Parameters analysed | Transient MCAO model | Permanent model | Age/ Weight | Gender | Litter-mates | Power | Operator- blinded | >24 h | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
NOX1 | mortality, infarct, edema, functional outcome | 30 min/23.5 h | ✗ | 11-17 wk | m | ✓ | n.s. | ✓ | ✗ | cortical but not total infarct ↑ in NOX1 KOs | [10] |
infarct, BBB, functional outcome, apoptosis, NOX1 mRNA + protein levels | 1/23 h and 2/22 h | pMCAO | n.s. | m | ✓ | n.s. | n.s. | ✗ | NOX1 KOs protected | [11] | |
mortality, infarct, edema/BBB, functional outcome, hemorraghe, NOX1 mRNA +  protein levels, ROS + RNS, apoptosis. | 1/23 h and 1 h/6d | pMCAO, cortical PT | 6-8 wk | m | ✗ | 93% | ✓ | 6 d | no significant difference | [12] | |
NOX2 | infarct, ROS, neutrophils | 2/22 h | ✗ | 8-10 wk | m | ✓ | n.s. | n.s. | ✗ | NOX2 KOs protected but not with WT bone marrow implant | [13] |
infarct, ROS | 25 min/3d | ✗ | 6 wk | m | ✓ | n.s. | n.s. | 3 d | NOX2 KOs protected | [14] | |
infarct, BBB | 2/22 h | ✗ | 7-9 wk | m | ✗ | n.s. | n.s. | ✗ | NOX2 KOs protected | [15] | |
infarct, functional outcome, oxidative stress, cell death, neutrophils, inflammation | 75 min/22.75 h and 75 min/3d | ✗ | 12-16 wk | m | ✗ | n.s. | n.s. | 3 d | NOX2 KOs protected | [16] | |
mortality, infarct, functional outcome, ROS | 30 min/23.5 h | ✗ | 6-8 wk | m | ✗ | n.s. | ✓ | ✗ | NOX2 KOs protected | [17] | |
infarct, edema, functional outcome, NOX2 protein levels, ROS. | 30 min/23.5 h and 30 min/3d | pMCAO | 6-8 wk | m + f | ✗ | n.s. | ✓ | 3 d | only male NOX2 KOs protected | [18] | |
mortality, infarct, edema/BBB, functional outcome, hemorraghe, mRNA + protein levels, ROS + RNS, apoptosis. | 1/23 h and 1 h/6d | pMCAO, cortical PT | 6-8 wk and 18–20 wk (unpublished) | m | ✗ | 93% | ✓ | 6 d | no significant difference | [12] | |
infarct, RNS, cell death, inflammatory markers | 75 min/24 h and 75 min/72 h | ✗ | 12-16 wk | m | ✗ | n.s. | n.s. | 3 d | NOX2 KOs protected | [19] | |
infarct, BBB, functional outcome, hemorraghe, ROS | 2/22 h | ✗ | 25-30 g | m | ✗ | n.s. | n.s. | ✗ | NOX2 KOs protected | [20] | |
mortality, infarct, edema, functional outcome, NOX2 protein levels, ROS + RNS, NO function. | 30 min/23.5 h | ✗ | 8-12 wk | m | ✗ | n.s. | ✓ | ✗ | NOX2 KOs protected | [21] | |
NOX4 | mortality, infarct, edema/BBB, functional outcome, hemorraghe, mRNA + protein levels, ROS + RNS, apoptosis. | 1/23 h and 1 h/6d | pMCAO, cortical PT | 6-8 wk and 18–20 wk | m + f | ✗ | 93% | ✓ | 6 d | NOX4 KOs protected | [12] |